CD44 and Patent ductus arteriosus: Generally, KLF4 inhibits PDA progression by binding to various promoters of genes related to proliferation, e.g., p21, p27Kip1, CD44, MSI2, Caveolin-1, and FOXM1 [50–52, 94, 95, 141].